It's All Immunotherapy Nowadays

OncoPharm
23/02/2018 17 min
It's All Immunotherapy Nowadays

Listen "It's All Immunotherapy Nowadays"

Descargar episodio Ver en sitio original

Episode Synopsis

Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA